全球對比增強型乳房 X 光檢查市場規模、佔有率、成長分析，依應用（篩檢和診斷）、最終用戶（醫院、診斷中心）- 2024-2031 年產業預測

Global Contrast Enhanced Mammography Market Size, Share, Growth Analysis, By Applications(Screening and Diagnosis), By End User(Hospital, Diagnostic Centres) - Industry Forecast 2024-2031

出版日期: 2024年04月29日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022 年，全球增強型乳房X 光攝影市場規模為18.4 億美元，預計將從2023 年的19.4 億美元成長到2031 年的29.2 億美元，預測期內（2024-2031 年）複合年成長率為5.28 %

對比增強乳房 X 光檢查 (CEM) 採用雙能量方法，結合了數位乳房 X 光檢查與靜脈注射顯影劑的優點。與單獨的全視野數位乳房 X 光攝影 (FFDM) 以及 FFDM 與超音波相結合在診斷環境中檢測乳癌時，CEM 表現出更高的靈敏度。鑑於全球乳癌發生率不斷上升，對比增強乳房X光檢查（CEM）已成為廣泛採用且流行的技術。多種因素會導致乳癌風險增加，包括年齡成長、肥胖、過量飲酒、乳癌家族史、先前接觸過輻射、生育史（例如首次月經和分娩的年齡）、吸煙和停經後荷爾蒙療法。大多數乳癌病例主要影響女性，影響很大一部分人口，通常起源於乳房組織。乳癌表現為多種症狀，包括乳房腫塊、乳房大小和形狀的改變、乳頭溢液以及皮膚變化，如搔癢、鱗屑和發紅。此外，這種疾病的進展可能會導致其他症狀，如骨痛、淋巴結腫脹、呼吸困難等，這表明疾病正在蔓延。因此，全球乳癌盛行率的增加成為市場擴張的催化劑。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2023 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率 (%), 2023

主要公司簡介

Hologic Inc.
GE Healthcare
Siemens Healthineers AG
Koninklijke Philips NV
Fujifilm Holdings Corporation
Dilon Technologies Inc.
Planmed Oy
Metaltronica SpA
CMR Naviscan Corporation
General Medical Merate SpA
Delphinus Medical Technologies Inc.
Micrima Limited
KUB Technologies Inc.
Aurora Imaging Technology Inc.
Carestream Health Inc.
Planmed Oy
Zebra Medical Vision Ltd.
Volpara Health Technologies Ltd.
iCAD Inc.
Agfa-Gevaert NV
In 2021, Hologic, Inc. announced the launch of its new CEM technology, the Quantra 3.0 Breast Density Assessment software, which uses artificial intelligence to provide more accurate and consistent breast density measurements.
In 2021, Siemens Healthineers announced the launch of its new MAMMOMAT Revelation with 3D biopsy technology, which combines CEM, 3D mammography,, biopsy in a single exam. The system is designed to improve accuracy, and reduce patient discomfort.

簡介目錄

Product Code: SQMIG35G2123

Global contrast enhanced mammography market size was valued at USD 1.84 billion in 2022 and is poised to grow from USD 1.94 billion in 2023 to USD 2.92 billion by 2031, at a CAGR of 5.28% during the forecast period (2024-2031)

Utilizing a dual-energy approach, contrast-enhanced mammography (CEM) combines the advantages of digital mammography with intravenous contrast administration. CEM exhibits higher sensitivity compared to full-field digital mammography (FFDM) alone and FFDM coupled with ultrasound in the detection of breast cancer within diagnostic settings. Given the escalating global incidence of breast cancer, contrast enhanced mammography (CEM) has emerged as a widely adopted and prevalent technique. Various factors contribute to the increased risk of breast cancer, including advancing age, obesity, excessive alcohol consumption, family history of breast cancer, past exposure to radiation, reproductive history (such as age at first menstruation and childbirth), tobacco usage, and postmenopausal hormone therapy. The majority of breast cancer cases predominantly affect females, impacting a significant portion of the population, usually originating in breast tissues. Breast cancer manifests through various symptoms, including breast lumps, alterations in breast size and shape, nipple discharge, as well as skin changes like itchiness, scaliness, and redness. Moreover, the progression of this disorder may result in additional symptoms such as bone pain, lymph node swelling, breathing difficulties, among others, signifying the spread of the disease. Consequently, the increasing prevalence of breast cancer globally serves as a catalyst for the expansion of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the global contrast enhanced mammography market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contrast Enhanced Mammography Market Segmental Analysis

Global contrast enhanced mammography market is segmented based on applications, end user, and region. By applications, the market is segmented into screening, and diagnosis. By end user, the market is segmented into hospital, diagnostic centres, specialty clinics, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Contrast Enhanced Mammography Market

The primary driver of market growth is the increasing prevalence of breast cancer, which ranks as the most frequently diagnosed cancer among women globally. Early diagnosis significantly enhances the effectiveness of breast cancer treatment. Typically, patients undergo a combination of surgical procedures, radiation therapy, and medications like hormone therapy, chemotherapy, and targeted biological therapy to address microscopic cancer cells that may have spread from the original tumor. These treatments play a crucial role in halting the growth and spread of cancer, ultimately saving lives.

Restraints in the Global Contrast Enhanced Mammography Market

Contrast-enhanced mammography represents a newer technology in the field, accompanied by higher costs compared to traditional mammography. The expenses involved in acquiring equipment, materials, and providing necessary training for contrast-enhanced mammography pose significant barriers to its widespread adoption. Additionally, the availability of contrast-enhanced mammography remains limited, with a scarcity of facilities offering this technology, particularly in rural or remote areas. Regulatory approval is a prerequisite before contrast-enhanced mammography can be integrated into clinical practice, a process known for its lengthiness and expense, potentially delaying the technology's market entry. Furthermore, despite promising outcomes demonstrated in clinical studies, the absence of long-term data on its efficacy and safety may instill hesitation among healthcare providers regarding its adoption until more robust evidence becomes available.

Market Trends of the Global Contrast Enhanced Mammography Market

Each year witnesses a surge in breast cancer cases among women, driving the expansion of the market and the proliferation of available treatments. Advanced technologies have revolutionized breast cancer diagnostics, offering enhanced techniques for detection. These sophisticated technologies have significantly improved performance metrics such as efficiency, accuracy, efficacy, reliability, and speed of results, thereby facilitating early detection and intervention.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Contrast Enhanced Mammography Market by Applications

Market Overview
Screening and Diagnosis

Global Contrast Enhanced Mammography Market by End User

Market Overview
Hospital
Diagnostic Centres
Specialty Clinics
Others

Global Contrast Enhanced Mammography Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Hologic Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koninklijke Philips N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Holdings Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dilon Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Planmed Oy
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metaltronica S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CMR Naviscan Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
General Medical Merate S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Delphinus Medical Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Micrima Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KUB Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurora Imaging Technology Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carestream Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Planmed Oy
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zebra Medical Vision Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Volpara Health Technologies Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
iCAD Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agfa-Gevaert NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In 2021, Hologic, Inc. announced the launch of its new CEM technology, the Quantra 3.0 Breast Density Assessment software, which uses artificial intelligence to provide more accurate and consistent breast density measurements.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In 2021, Siemens Healthineers announced the launch of its new MAMMOMAT Revelation with 3D biopsy technology, which combines CEM, 3D mammography, and biopsy in a single exam. The system is designed to improve accuracy and reduce patient discomfort.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments